Additional file 1 of Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation

Additional file 1 Supplementary Fig. 1. Identification of T and B cell phenotypes by 8-color antibody staining. Supplementary Fig. 2. Comparison of the actual number of peripheral blood IgM unswitched memory B cells and IgG-CD27- B cells between healthy controls and patients with ANCA-related vasculitis. Supplementary Fig. 3. Correlations between the proportion of peripheral class switched memory B cells and IgD-CD27- B cells at baseline. Supplementary Fig. 4. Comparison between rates of BVAS improvement 6 months after the beginning of remission induction therapy in the RTX and IV-CY groups according to disease type (MPA and GPA) and presence/absence of excessive B cell differentiation. Supplementary Fig. 5. Association between plasmablasts and resistance to treatment. Supplementary Fig. 6. Changes in the rate of glucocorticoid reduction in patients with and without excessive B cell differentiation by treatment group. Supplementary Table S1. Eight-color antibody panels used in the study. Supplementary Table S2. Differences in the proportions of circulating T cell and B cell phenotypes between patients with AAV at baseline and sex-matched healthy control subjects. Supplementary Table S3. Correlation between disease activity at baseline or rate of improvement in BVAS and the proportion of circulating T cell and B cell phenotypes. Supplementary Table S4. Baseline characteristics of AAV patients with and without excessive B cell differentiation. Supplementary Table S5. Differences in proportions of circulating T cells between AAV patients with and without excessive B cell differentiation.